Literature DB >> 8652273

Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys.

K H Heider1, J W Mulder, E Ostermann, S Susani, E Patzelt, S T Pals, G R Adolf.   

Abstract

Certain isoforms of the CD44 glycoprotein family play an essential role in the metastatic spread of tumour cells. Protein expression of such CD44 isoforms has also been observed in a variety of human malignancies. In this study, we compared the expression of exon v5- and v6-containing CD44 isoforms in normal human and cynomolgus monkey (Macacca fasciculata) tissues. Cloning and sequencing of cynomolgus CD44 exons v5 and v6 revealed a homology of 97% and 95%, respectively, between man and monkey. Two monoclonal antibodies (MAbs) directed against an epitope encoded by human exon v5 (VFF8) and an epitope encoded by exon v6 (VFF18) were used to determine expression of CD44 isoforms in man and monkey. Immunohistochemical screening of a representative profile of normal human and cynomolgus tissues revealed that expression of exon v5- and v6-containing CD44 isoforms was almost identical in the two species. Exon v6 staining was observed only in a subset of epithelial tissues, whereas v5 staining was additionally detected on certain non-epithelial tissues. These data suggest that cynomolgus monkey could serve as a system to test the usefulness of antivariant CD44 MAbs with regard to antibody-based tumour therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8652273     DOI: 10.1016/0959-8049(95)00420-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Forms and functions of CD44.

Authors:  G Borland; J A Ross; K Guy
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

2.  Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn's disease.

Authors:  W Reinisch; K H Heider; G Oberhuber; C Dejaco; M Müllner; G R Adolf; C Gasché
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

3.  CD44 standard and variant isoform expression in normal human skin appendages and epidermis.

Authors:  W K Seelentag; U Günthert; P Saremaslani; E Futo; M Pfaltz; P U Heitz; J Roth
Journal:  Histochem Cell Biol       Date:  1996-09       Impact factor: 4.304

Review 4.  Targeted therapy in head and neck cancer.

Authors:  S K Kundu; M Nestor
Journal:  Tumour Biol       Date:  2012-02-29

Review 5.  CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches.

Authors:  Diana Spiegelberg; Johan Nilvebrant
Journal:  Contrast Media Mol Imaging       Date:  2017-06-20       Impact factor: 3.161

6.  Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.

Authors:  Anja C Mortensen; Diana Spiegelberg; Anna-Karin Haylock; Hans Lundqvist; Marika Nestor
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

7.  Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers.

Authors:  Anna-Karin Haylock; Johan Nilvebrant; Anja Mortensen; Irina Velikyan; Marika Nestor; Ronny Falk
Journal:  Oncotarget       Date:  2017-05-18

8.  In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study.

Authors:  Anna-Karin Haylock; Diana Spiegelberg; Johan Nilvebrant; Karl Sandström; Marika Nestor
Journal:  EJNMMI Res       Date:  2014-03-06       Impact factor: 3.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.